Introduction
============

Hydrogen sulfide (H~2~S) is a colorless, watersoluble gas with a smell of rotten eggs and is an endogenously produced labile diffusible mediator with multiple roles in the cardiovascular system in health and disease. H~2~S is endogenously generated, and cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) are key enzymes involved in its biological production ([@B1]-[@B3]). Although the physiological effect of H~2~S is not yet clear, it is known to influence cardiovascular homoeostasis, such as through vasodilation, pro-apoptotic activities in vascular smooth muscle, leukocyte-endothelium interaction, and suppression of oxidative stress ([@B3]-[@B6]). We previously reported that, in hyperglycemic endothelial cells and streptozotocin-induced diabetes in rats, hyperglycemia is associated with increased H~2~S degradation, as the H~2~S concentrations in the media and plasma were decreased. In addition, H~2~S replacement relieved oxidative stress and improved the endothelial metabolic states. Brancaleone et al. demonstrated that vascular dilation, H~2~S biosynthesis, and H~2~S endogenous production progressively contribute to the severity of diabetes in non-obese diabetic mice ([@B7]). However, little has been reported on plasma H~2~S levels in type 2 diabetic patients, particularly Japanese patients.

In the present study, we examined the plasma H~2~S levels in patients with type 2 diabetes and evaluated the relevance of H~2~S to the history of cardiovascular disease in these patients.

Materials and Methods
=====================

This randomized pilot study was conducted on 200 randomly selected patients with type 2 diabetes from the 626 outpatients who had visited this institution for type 2 diabetes and 100 without diabetes from the 308 outpatients without diabetes who had visited for hypertension, dyslipidemia, or thyroid disease controlled satisfactorily by medication. The exclusion criteria were 1) severe ketosis and diabetic coma, 2) severe complication of diabetes, 3) renal insufficiency (serum creatinine level \>1.5 mg/dL in men or \>1.3 mg/dL in women) and liver dysfunction, 4) severe infection, 5) pregnant or nursing women and those who might be pregnant, 6) alcoholism, and 7) any patients whom the investigators judged to be inappropriate for this study. Ultimately, 154 patients with type 2 diabetes and 66 without diabetes were enrolled.

All of the blood and samples were collected in the outpatient department from 09:00 to 10:00. The patients had fasted from 21:00 the previous evening and had not consumed alcohol or caffeine or smoked until sample collection. This study was approved by the Ethics Committee of Dokkyo Medical University (Tochigi, Japan). The Clinical Trial registration no. is UMIN000020549. All of the subjects provided their written informed consent. This study was designed in accordance with the principles stated in the Declaration of Helsinki.

The blood samples to measure the plasma H~2~S levels were collected in an EDTA anti-coagulated tube. The plasma H~2~S levels were determined in triplicate, and the average concentrations were calculated against a calibration curve of sodium sulfide (Sigma-Aldrich, MO, USA).

Briefly, as described previously ([@B7]-[@B10]), the plasma samples (100 μM) were added to sealed Eppendorf tubes containing 200 μL zinc acetate (1% wt/vol). Then, 100 μL N,N-dimethyl-*p*-phenylenediamine sulfate (20 mM, in 7.2 M HCl) and 133 μL FeCl3 (30 mM, in 1.2 M HCl) were added. After incubation at 37℃ in the dark for 30 minutes, the samples were centrifuged at 5,000 g for 10 minutes, and the absorbance was measured at 670 nm.

The data are presented as the means ± standard deviation (SD). The differences between the groups were analyzed using Student\'s paired or unpaired *t-*test. The differences in the non-parametric data were analyzed using the Mann-Whitney U-test and Wilcoxon\'s matched pairs test. Univariate and multivariate logistic regression analyses were performed to assess whether each clinical marker correlated with the plasma H~2~S levels. Values of p\<0.05 were considered significant. All of the analyses were performed using Prism 6 (GraphPad Software, Inc., San Diego, CA, USA) and Stat Mate V (Nihon 3B Scientific, Inc., Niigata, Japan).

Results
=======

The participants\' demographics are shown in [Table 1](#t001){ref-type="table"}. The plasma H~2~S levels were significantly lower in patients with type 2 diabetes than in those without (45.1±15.5 μM versus 54.0±26.4 μM, p\<0.05; [Figure a](#g001){ref-type="fig"}). All of the patients with type 2 diabetes having poor glycemic control exhibited a progressive reduction in plasma H~2~S levels as well as HbA1c levels ([Figure b](#g001){ref-type="fig"}). Furthermore, the plasma H~2~S levels in patients with type 2 diabetes with a history of cardiovascular disease (non-fetal cerebrovascular disease, coronary artery disease, and peripheral artery disease) were significantly lower than those in patients with type 2 diabetes without cardiovascular disease (39.9±13.8 μM versus 47.5±15.9 μM, p\<0.01) ([Figure c](#g001){ref-type="fig"}). In the univariate analysis, the plasma H~2~S levels were negatively correlated with the HbA1c level (γ=-0.730, p\<0.001), duration of diabetes (γ=-0.689, p\<0.001), systolic blood pressure (γ=-0.203, p\<0.05), and diastolic blood pressure (γ=-0.165, p\<0.05). A stepwise regression analysis including significant variables was performed. The HbA1c level (β=0.505, p\<0.01) was an independent determinant of plasma H~2~S levels ([Table 2](#t002){ref-type="table"}).

###### 

Clinical Characteristic of the Study Participants.

                                         Type 2 diabetes    Non-Type 2 diabetes   p value
  -------------------------------------- ------------------ --------------------- ----------
  Patients (M/F)                         154 (67/87)        66 (25/41)            \< 0.001
  Age (years)                            61.7 ± 13.6        52.5 ± 14.8           \< 0.001
  Body mass index (kg/m^2^)              25.3 ± 4.7         24.1 ± 5.6            \< 0.05
  HbA1c, % (NGSP)                        7.6 ± 1.6          5.7 ± 0.8             \< 0.001
  Duration of diabetes (years)           13.2 ± 9.1         \-                    \-
  eGFR (mL/min/1.73m^2^)                 78.3 ± 29.3        84.9 ± 32.6           0.136
  Urinary albumin excretion (μg/g Cre)   28.5 (3.0-151.8)   4.0 (3.0-8.0)         \< 0.001
  ACEI or ARB, n (%)                     85 (55.2%)         13 (19.6%)            \< 0.001
  Statins, n (%)                         65 (42.2%)         22 (33.3%)            \< 0.01
  LDL-C (mg/dL)                          102.3 ± 28.9       114.3 ± 45.0          0.180
  HDL-C (mg/dL)                          55.9 ± 14.6        69.5 ± 23.8           \< 0.001
  Triglyceride (mg/dL)                   130.4 ± 67.4       127.1 ± 76.5          0.239
  Systolic Blood Pressure (mmHg)         131.5 ± 15.5       119.8 ± 20.4          \< 0.001
  Diastolic Blood Pressure (mmHg)        73.5 ± 11.1        67.8 ± 13.0           \< 0.05

Data are mean ± SD or median and interquartile range.

HbA1c: hemoglobin A1c, eGFR: estimated glomerular filtration rate,

ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker,

LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol

![The plasma H~2~S levels in patients with and without type 2 diabetes. (a) A comparison of the patients with and without type 2 diabetes. (b) The influence of glycemic control on the plasma H~2~S levels. (c) The relationship between a history of cardiovascular disease (CVD) and the plasma H~2~S levels in patients with type 2 diabetes.](1349-7235-56-0017-g001){#g001}

###### 

Univariate and Multivariate Analysis for Association with Each Variable with Hydrogen Sulfide Levels.

                                         Univariate   Multivariate            
  -------------------------------------- ------------ -------------- -------- -------
  Age (years)                            -0.069       0.387          \-       \-
  Body mass index (kg/m^2^)              -0.067       0.401          \-       \-
  HbA1c, % (NGSP)                        -0.730       \< 0.001       -0.505   0.001
  Fasting glucose per mg/dL              0.050        0.438          \-       \-
  duration of diabetes yrs               -0.689       \< 0.001       0.006    0.937
  Systolic Blood Pressure (mmHg)         -0.203       \< 0.05        -0.108   0.154
  Diastolic Blood Pressure (mmHg)        -0.165       \< 0.05        -0.090   0.311
  LDL-C (mg/dL)                          -0.049       0.552          \-       \-
  HDL-C (mg/dL)                          -0.045       0.59           \-       \-
  Triglyceride (mg/dL)                   0.128        0.08           \-       \-
  eGFR (mL/min/1.73m^2^)                 -0.003       0.975          \-       \-
  Urinary albumin excretion (μg/g∙Cre)   -0.138       0.102                   
  R^2^                                                               0.58     

HbA1c: hemoglobin A1c, eGFR: estimated glomerular filtration rate,

LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol

Discussion
==========

H~2~S is the most recent of three endogenously produced molecules to be discovered and termed a gasotransmitter, along with nitric oxide (NO) and carbon monoxide (CO) ([@B11]). While initially considered to be toxic, researchers have discovered that these gasotransmitters are endogenously produced at low levels and induce compensatory and protective physiological changes ([@B12]). The first gasotransmitter, NO, was discovered in the 18th century but was found in 1987 to be an endogenous vasodilator in mammals through its generation by NO synthase ([@B13]). NO is not only a mediator of endothelium-dependent vasodilation but also has anti-inflammatory and antithrombotic effects, as well as an impact on the development of atherosclerosis ([@B14]). The second gasotransmitter, CO, is a vital cardiovascular mediator that upregulates the protective mechanisms at a low physiologic concentration ([@B15]). The third gasotransmitter, H~2~S, was found to play an important role in mediating physiological processes. H~2~S has been shown to modulate the metabolic state, vascular reactivity, and systolic blood pressure ([@B1],[@B16]). The present data demonstrated that plasma H~2~S levels are significantly reduced in patients with type 2 diabetes, particularly in those with a history of cardiovascular disease. This study is the first report to determine the plasma H~2~S levels in a large group of Japanese patients with type 2 diabetes.

H~2~S is an important endogenous vasodilatory intermediate that induces endothelial vasodilatation though the K~ATP~ channel *in vitro* and *in vivo* ([@B17]). Type 2 diabetes is likely to be associated with the development of hypertension, hypercholesterolemia, diabetes-related complications, and heart failure ([@B18],[@B19]). However, the precise molecular mechanism underlying why these complications occur in patients with diabetes is still unclear. The current study revealed that plasma H~2~S levels are reduced in patients with type 2 diabetes mellitus compared to those without, which may influence the occurrence of atherosclerotic disease. Many studies have reported the beneficial effects of H~2~S replacement therapy using H~2~S donors in several organs and have also observed neuroprotective effects ([@B20]) of the liver and lungs from ischemia-reperfusion injury in a rat model ([@B21],[@B22]). Furthermore, H~2~S has been shown to be an antioxidant itself and can upregulate the antioxidant protective mechanism ([@B23]). These effects of H~2~S may be salutary to a number of cardiovascular disease states, including diabetes.

Our current study showed that plasma H~2~S levels negatively correlated with HbA1c, duration of diabetes, and systolic and diastolic blood pressures. The most interesting finding was that glycemic control was the major determinant of the plasma H~2~S levels, which reflect the HbA1c levels. In addition, Brancaleone et al. reported that biosynthesis of H~2~S is impaired in diabetic mice, and endogenous H~2~S production is more impaired in diabetic mice with more severe glycemia than in those with less severe glycemia ([@B6]). In our study, the peripheral endothelial function was assessed in 32 of 154 type 2 diabetes patients using reactive hyperemia peripheral arterial tonometry (RH-PAT) with an EndoPAT2000 (Itamar Medical, Caesarea, Israel) as described previously ([@B24]). The endothelial function was also positively correlated with the plasma H~2~S levels (γ=0.467, p\<0.01). A previous study demonstrated that the plasma H~2~S levels likely contribute to the endothelium-dependent relaxant function in diabetic rodents ([@B6],[@B25]), which is consistent with our findings for type 2 diabetes patients.

Regarding the possible clinical application of H~2~S-releasing drugs, H~2~S exerts a number of cytoprotective and anti-inflammatory effects in many organ systems. A number of H~2~S-releasing derivatives of existing drugs have been developed and extensively tested in preclinical models ([@B26]). H~2~S-releasing drugs are expected to have the beneficial effects of endogenous gaseous mediators in the gastrointestinal tract, which include reducing the gastrointestinal ulceration and bleeding caused by nonsteroidal anti-inflammatory drugs, as well as in the cardiovascular-protecting systems ([@B27]).

Several limitations associated with the present study warrant mention. First, the plasma H~2~S levels in the present study were measured using the methylene blue assay, which indicates the sulfide concentrations through colorimetry and may not be entirely accurate because of the interference and artifacts ([@B28]). Fluorescent probe detection is another method that could be used for H~2~S level detection. However, H~2~S catabolism occurs rapidly, which could result in fluctuation of the H~2~S concentration; therefore, it may be difficult to accurately analyze this important molecule ([@B29]). Second, we were unable to assess the endothelial function in all of the type 2 diabetes patients using the EndoPAT2000.

In conclusion, this study showed that the plasma H~2~S levels are significantly reduced in type 2 diabetes patients, particularly in those with a history of cardiovascular disease. The plasma H~2~S levels in patients with type 2 diabetes may reflect the HbA1c levels. Further studies are warranted to investigate the relationship between the plasma H~2~S levels and diabetes and related complications, particularly cardiovascular diseases.
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